384 related articles for article (PubMed ID: 30995665)
61. Accuracy and clinical correlates of two different methods for chromogranin A assay in neuroendocrine tumors.
Ferrari L; Seregni E; Lucignani G; Bajetta E; Martinetti A; Aliberti G; Pallotti F; Procopio G; Della Torre S; Luksch R; Bombardieri E
Int J Biol Markers; 2004; 19(4):295-304. PubMed ID: 15646836
[TBL] [Abstract][Full Text] [Related]
62. Diagnostic value of circulating chromogranin a for neuroendocrine tumors: a systematic review and meta-analysis.
Yang X; Yang Y; Li Z; Cheng C; Yang T; Wang C; Liu L; Liu S
PLoS One; 2015; 10(4):e0124884. PubMed ID: 25894842
[TBL] [Abstract][Full Text] [Related]
63. Improved diagnostic accuracy for neuroendocrine neoplasms using two chromogranin A assays.
Ramachandran R; Bech P; Murphy KG; Dhillo WS; Meeran KM; Chapman RS; Caplin M; Ghatei MA; Bloom SR; Martin NM
Clin Endocrinol (Oxf); 2012 Jun; 76(6):831-6. PubMed ID: 22175276
[TBL] [Abstract][Full Text] [Related]
64. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
65. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
Kidd M; Drozdov IA; Matar S; Gurunlian N; Ferranti NJ; Malczewska A; Bennett P; Bodei L; Modlin IM
PLoS One; 2019; 14(6):e0218592. PubMed ID: 31247038
[TBL] [Abstract][Full Text] [Related]
66. Chromogranin As a Biochemical Marker of Neuroendocrine Tumors.
Lyubimova NV; Churikova TK; Kushlinskii NE
Bull Exp Biol Med; 2016 Mar; 160(5):702-4. PubMed ID: 27021085
[TBL] [Abstract][Full Text] [Related]
67. Concordance between results of somatostatin receptor scintigraphy with 111In-DOTA-DPhe 1-Tyr 3-octreotide and chromogranin A assay in patients with neuroendocrine tumours.
Rodrigues M; Gabriel M; Heute D; Putzer D; Griesmacher A; Virgolini I
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1796-802. PubMed ID: 18425512
[TBL] [Abstract][Full Text] [Related]
68. Circulating Chromogranin A as A Marker for Monitoring Clinical Response in Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Tian T; Gao J; Li N; Li Y; Lu M; Li Z; Lu Z; Li J; Shen L
PLoS One; 2016; 11(5):e0154679. PubMed ID: 27159453
[TBL] [Abstract][Full Text] [Related]
69. Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.
Miki M; Ito T; Hijioka M; Lee L; Yasunaga K; Ueda K; Fujiyama T; Tachibana Y; Kawabe K; Jensen RT; Ogawa Y
Jpn J Clin Oncol; 2017 Jun; 47(6):520-528. PubMed ID: 28334992
[TBL] [Abstract][Full Text] [Related]
70. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
Yao JC; Pavel M; Phan AT; Kulke MH; Hoosen S; St Peter J; Cherfi A; Öberg KE
J Clin Endocrinol Metab; 2011 Dec; 96(12):3741-9. PubMed ID: 21994954
[TBL] [Abstract][Full Text] [Related]
71. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
72. [Usefulness of chromogranin A determination in the diagnosis of neuroendocrine neoplasia].
Militello C; Cannizzaro R; Pradella P; Volpin E; Spirch S; Buonadonna A; De Appollonia L; Rossi C; Sigon R; Cipresso S; Terranova O
Chir Ital; 1999; 51(1):45-51. PubMed ID: 10514916
[TBL] [Abstract][Full Text] [Related]
73. Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.
Fisher AV; Lopez-Aguiar AG; Rendell VR; Pokrzywa C; Rocha FG; Kanji ZS; Poultsides GA; Makris EA; Dillhoff ME; Beal EW; Fields RC; Panni RZ; Idrees K; Smith PM; Cho CS; Beems MV; Maithel SK; Winslow ER; Abbott DE; Weber SM
J Gastrointest Surg; 2019 Apr; 23(4):651-658. PubMed ID: 30659439
[TBL] [Abstract][Full Text] [Related]
74. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
75. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.
Corti A; Marcucci F; Bachetti T
Pflugers Arch; 2018 Jan; 470(1):199-210. PubMed ID: 29018988
[TBL] [Abstract][Full Text] [Related]
76. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
77. Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
Wang YC; Iezza G; Zuraek MB; Jablons DM; Theodore PR; Bergsland EK; Donner DB; Warren RS; Nakakura EK
J Surg Res; 2010 Sep; 163(1):47-51. PubMed ID: 20599218
[TBL] [Abstract][Full Text] [Related]
78. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma.
Lee SH; Jo JH; Kim YJ; Lee HS; Chung MJ; Park JY; Bang S; Park SW; Song SY
Pancreas; 2019; 48(5):662-669. PubMed ID: 31091213
[TBL] [Abstract][Full Text] [Related]
79. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
80. Molecular markers help characterize neuroendocrine lung tumors.
Rusch VW; Klimstra DS; Venkatraman ES
Ann Thorac Surg; 1996 Sep; 62(3):798-809; discussion 809-10. PubMed ID: 8784011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
